Result: ETVr substitutions at rtT184 (rtT184C/G/I/S) have been shown to exhibit low-level ETVr and have only been observed in combination with other ETVr substitutions in patients with virologic breakthrough.( 12 ) The novel emergent rtV191I substitution was phenotyped in an ETVr HBV RT b
Result: One patient infected with HBV genotype B experienced virologic breakthrough with detection of a novel substitution rtS202V in combination with rtT184G and LVDr substitutions rtL180M+rtM204V.
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Method: Mutation of rtI169T (0.12%), rtT184G (0.06%), rtA194T (0.07%), and rtM250V/L (0.20%) had a very low pooled incidence (Figure 1).
HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining.
Introduction: According to several clinical practice guidelines and authoritative reviews, NUCr substitutions can be classified into two categories: primary NUCr substitutions at 8 codons (rtI169T, rt
Introduction: Resistance to ETV needs a combination of substitutions of rtM204I/V and rtL180M plus one of the following substitutions: rtI169T, rtT184A/C/F/G/I/L/M/S, rtS202C/G/I or rtM250I/L/V.
Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China.
PMID: 26876337
2016
The Brazilian journal of infectious diseases
Abstract: Mutations in HBV DNA polymerase were detected in 24 patients (8.9%) including rtM204I/V (n=6), rtN236T (n=5), rtM250V (n=2), rtL180M (n=2), rtT184G (n=1), rtM207I (n=1), rtS202I (n=1), rtM204V/I & rtL180M (n=5), and rtM204I &
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).
Establishment of drug-resistant HBV small-animal models by hydrodynamic injection.
Result: It is worth noting that we did not observe any of the common NA-related resistance mutations including rtM204V/I, rtS202C/G/I, rtL180M, rtA181T/V, rtT184A/I/L/G/C/M, rtA194T, rtI169T, rtV173L, rtL80I, rtN236T, and PMID: 24497877
2014
Hepatitis monthly
Abstract: A number of significant drug resistant mutations were found in five patients including S202I, N236T, M250L, L180M/V, M204I, A181T, T184G, M250V, and V173L.
Result: Patient 247131 was found to have mutations L180M, M204I, T184G, and M250V, which were associated with resistance to lamivudine, entecavir, emitricitabine, famciclovir, and telbivudine.
Table: T184G
Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naive chronic HBV patients.
Introduction: Interestingly, resistance to ETV includes LAM resistance mutations, rtM250V+-rtI169T+rtM204V+rtL180M and rtT184G+rtS202I+rtM204V+rtL180M.
HBV mutation literature information.
PMID: 
2018
Hepatology communications
Browser Board
Co-occurred Entities
Filtrator
ViMRT